Advanced Therapies in Belgium

Two major steps in bringing safe and effective exosome-based therapies to patients worldwide.

🇧🇪 🇧🇷 Belgium and Brazil Unite to Advance RNA-Based Therapies: MoU Signed Between Bio-Manguinhos / Fiocruz, Quantoom Biosciences, and UNIVERCELLS in the presence of Her Royal Highness Princess Astrid of Belgium during the Belgian Economic Mission to Brazil. An inspiring example of the power of international collaboration in addressing global health challenges, combining expertise to expand access to innovative health solutions. 👉 Read the full relase: https://lnkd.in/egpe4gcD

Major milestone for innovation in cell therapy! Cellistic has just announced the successful GMP certification of its first-of-its kind facility dedicated to iPSC-based allogeneic cell therapies. This achievement signifies Cellistic’s quality and regulatory readiness, which is now certified by the Belgian Federal Agency for Medicines and Health Products (FAMHP), operating under European Medicines Agency (EMA) guidelines. “Cellistic’s mission has always been to pave the way to accessible cell therapies, making treatment more available to patients,” says Gustavo Mahler PhD, CEO of Cellistic. “Our deep expertise in iPSC reprogramming, gene editing, and differentiation, combined with this expanded manufacturing capability, makes Cellistic a trusted partner for innovators looking to bring cell therapies to the clinic. We’re excited to provide scalable, GMP-compliant solutions that support our clients at every stage, from initial development through to commercialization.” ➡️ Read the full release: https://lnkd.in/evqj53RH

Ready to team up with researchers/companies in the field of advanced therapies? On December 10, KU Leuven scientists and business professionals active in the domain of Advanced Therapy Medicinal Products (ATMP) can join forces at this free matchmaking event in Heverlee. On the programme of the event, that starts at 17:30, are talks by Evelien Stalmeijer (eXmoor pharma), Bart Geers (KU Leuven Research & Development), and other experts, followed by a networking reception and the opportunity to establish contacts through the Conversation Starter platform. --- Practical information: 📅 Tuesday 10 December 2024 📍 Bio-Incubator (Gaston Geenslaan 3, Heverlee) 🕒 Welcome from 17:30 🎤 Full program: https://lnkd.in/eNpvHq5F The event is free of charge, but registration is required before December 3rd. 👉 https://lnkd.in/e-5EWWjv ‘Know your niche’ is an initiative by KU Leuven Research & Development and Smart Hub Vlaams-Brabant, supported by MEDVIA and flanders.bio.

What’s next for gene and cell therapy in Belgium? Find out on November 29 at ULiège - RISE, where Jiri Keirsse and Laetitia Malphettes (UCB), Emmanuel Di Valentin (GIGA, ULiège), Géraldine Piel, and Manon Berger (CIRM ULiège) will share insights on viral and non-viral vectors. You will also learn about the GT4Health project — a collaboration between the 5 Belgium’s French-speaking universities and the CER Groupe driving innovation in gene therapy. Service public de Wallonie, S3 Wallonia | Smart Specialisation Strategy, CIRM ULiège GIGA - Université de Liège, University of Liège, UMONS, UNamur - Recherche, Université libre de Bruxelles, Université catholique de Louvain https://lnkd.in/e9QxQemM

Advanced Therapies in Belgium brought together industry professionals from the forefront of the Belgian and international ATMP innovation to advance the development and access to next-generation therapies for patients. Let’s look back and relive the inspirational discussions. Were you at the event? What did you think? Should we repeat it next year? Let us know in the comments 👇🏻 BioWin, MEDVIA, Wallonia Export & Investment Agency

What is the Belgian recipe for an innovative ecosystem in advanced therapies? Read this interesting Paper from Deloitte, developed with input from BioWin and MEDVIA. It addresses the challenges in commercialising advanced therapies and highlights Belgium’s potential to become a biomanufacturing hub in Europe, thanks to its strong logistics, academic expertise, and infrastructure. 👉 Download the full report: https://lnkd.in/eKrAT5UP

When innovators get together, good things happen. That was the case last Tuesday at the Advanced Therapies in Belgium event, organised by BioWin and MEDVIA. Key event highlights: 250+ ATMP experts from Belgium and key international stakeholders 175+ organisations, including startups, hospitals, universities & companies. 420+ partnering requests, highlighting interest in collaborative innovation. 280+ scheduled meetings, with plenty of potential partnerships ahead. Thank you to our sponsors, exhibitors, speakers, pitchers, supporters and participants! And a huge thank you to all of the strategic sponsors who made the event possible, including: UCB, Thermo Fisher Scientific, Aseptic Technologies, Johnson & Johnson, Deloitte, Wallonia Export & Investment Agency

💥 They will be pitching at Advanced Therapies in Belgium, come and listen to them. - Advanced therapy developers: Cliniques universitaires Saint-Luc, VIB-VUB center of Structural Biology, HOGENT, NOVADIP Biosciences S.A., LiveDrop , The Center for Microscopy and Molecular Imaging, Thermo Fisher Scientific, University of Liège, PDC*line Pharma, Université catholique de Louvain - Industrial service providers: Cryoport Systems, Antleron, LifeSaver Project, Aseptic Technologies, 2 Bridge, Effex, AxTalis, ExoXpert, DNAlytics, Cell and Gene Therapy Catapult

Johnson & Johnson is one of the sponsors of our Advanced Therapies in Belgium event, bringing together 250+ industry experts tomorrow in Namur. Johnson & Johnson shares: "Our participation in the event provides a unique opportunity to share our innovations and learn from other innovators. By uniting the Flemish and Walloon regions, we foster collaboration that not only enhances networking but ultimately helps bring our innovations to patients, shaping the future of advanced therapies."